Stifel Nicolaus assumed coverage on shares of PerkinElmer (NYSE:PKI) in a research report report published on Thursday morning, The Fly reports. The brokerage issued a buy rating and a $102.00 price target on the medical research company’s stock.

Several other brokerages have also issued reports on PKI. Needham & Company LLC reiterated a hold rating on shares of PerkinElmer in a report on Thursday, October 31st. Wood & Company reiterated an average rating and set a $49.00 price target on shares of PerkinElmer in a report on Friday, July 19th. BMO Capital Markets lifted their price target on PerkinElmer from $50.00 to $52.00 and gave the company an outperform rating in a report on Wednesday, November 6th. UBS Group reduced their price target on PerkinElmer from $101.00 to $92.00 and set a neutral rating for the company in a report on Friday, October 18th. Finally, Raymond James reiterated an average rating and set a $51.00 price target on shares of PerkinElmer in a report on Tuesday, November 5th. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of Hold and an average target price of $73.59.

NYSE:PKI traded up $2.83 on Thursday, hitting $90.95. 748,774 shares of the company’s stock traded hands, compared to its average volume of 719,514. The company has a current ratio of 1.30, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70. PerkinElmer has a 1 year low of $71.83 and a 1 year high of $103.00. The firm has a 50-day moving average price of $85.11 and a 200-day moving average price of $88.21. The company has a market cap of $9.77 billion, a PE ratio of 25.19, a price-to-earnings-growth ratio of 1.60 and a beta of 1.29.

PerkinElmer (NYSE:PKI) last released its earnings results on Wednesday, October 30th. The medical research company reported $1.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.01 by $0.05. PerkinElmer had a return on equity of 16.45% and a net margin of 8.27%. The company had revenue of $706.92 million for the quarter, compared to analysts’ expectations of $722.69 million. During the same quarter in the previous year, the business posted $0.90 EPS. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. On average, research analysts forecast that PerkinElmer will post 4.08 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, February 7th. Investors of record on Friday, January 17th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, January 16th. This represents a $0.28 annualized dividend and a yield of 0.31%. PerkinElmer’s dividend payout ratio (DPR) is currently 7.76%.

In related news, Director Alexis P. Michas sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $82.56, for a total value of $165,120.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of PKI. Private Advisor Group LLC acquired a new position in shares of PerkinElmer during the second quarter worth approximately $225,000. Flinton Capital Management LLC lifted its holdings in shares of PerkinElmer by 3.9% during the second quarter. Flinton Capital Management LLC now owns 6,720 shares of the medical research company’s stock worth $647,000 after buying an additional 252 shares during the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of PerkinElmer by 117.8% during the second quarter. UBS Asset Management Americas Inc. now owns 275,337 shares of the medical research company’s stock worth $26,526,000 after buying an additional 148,947 shares during the last quarter. Palmer Knight Co lifted its holdings in shares of PerkinElmer by 0.3% during the second quarter. Palmer Knight Co now owns 58,521 shares of the medical research company’s stock worth $5,638,000 after buying an additional 179 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of PerkinElmer by 164.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,088 shares of the medical research company’s stock worth $1,743,000 after buying an additional 11,239 shares during the last quarter. Hedge funds and other institutional investors own 95.77% of the company’s stock.

About PerkinElmer

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Featured Article: How to find the components of the quick ratio

The Fly

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.